What Next for Arsanis Inc (NASDAQ:ASNS) Stock After Increase in Shorted Shares?

May 17, 2018 - By Graig Alexander

The stock of Arsanis Inc (NASDAQ:ASNS) registered an increase of 4.95% in short interest. ASNS’s total short interest was 169,600 shares in May as published by FINRA. Its up 4.95% from 161,600 shares, reported previously. With 17,800 shares average volume, it will take short sellers 10 days to cover their ASNS’s short positions. The short interest to Arsanis Inc’s float is 91.53%.

The stock decreased 0.35% or $0.07 during the last trading session, reaching $19.92. About 26,549 shares traded. Arsanis, Inc. (NASDAQ:ASNS) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address serious infectious diseases. The company has market cap of $284.74 million. The Company’s lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia. It currently has negative earnings. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

More important recent Arsanis, Inc. (NASDAQ:ASNS) news were published by: Benzinga.com which released: “36 Stocks Moving In Monday’s Mid-Day Session” on April 30, 2018, also Prnewswire.com published article titled: “Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical …”, Seekingalpha.com published: “Stocks To Watch: A Fed Head Talks Crypto” on May 13, 2018. More interesting news about Arsanis, Inc. (NASDAQ:ASNS) was released by: Businesswire.com and their article: “Arsanis Reports Business Highlights and Financial Results for First Quarter 2018” with publication date: May 10, 2018.

Arsanis, Inc. (NASDAQ:ASNS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.